Clinical-stage biotechnology company Turnstone Biologics Corp (Nasdaq:TSBX) on Friday announced a strategic restructuring to prioritise its pipeline and extend its financial runway.

The company plans to reduce its workforce by approximately 60% and realign resources to focus on the development of its TIDAL-01 clinical programme.

TIDAL-01 is currently being evaluated in multiple Phase 1 trials including patients with colorectal cancer, head and neck cancer, and uveal melanoma.

This restructuring is expected to extend Turnstone's cash runway by three additional quarters, into the second quarter of 2026. The company believes that this will enable it to build upon initial positive trial data.